Navigating EGFR-Mutated NSCLC: Clinical Insights for Pharmacists on Personalized Care
Cara Chang, PharmD, BCOP, provides comprehensive insights into the challenges, advances, and best practices in treating EGFR-positive non–small cell lung cancer (NSCLC), emphasizing the importance of molecular testing before treatment initiation, the evolution of targeted therapies and combination approaches, the critical role of pharmacists in medication management and patient education, and emerging treatments including subcutaneous amivantamab and antibody-drug conjugates that promise to improve outcomes while reducing toxicity.
EP. 1: Overcoming Challenges in NSCLC Management From a Pharmacist’s Perspective
April 18th 2025A panelist discusses how non–small cell lung cancer presents significant treatment challenges due to its prevalence, high mortality rate, poor 5-year survival outcomes, and the difficulty of managing patients with advanced disease who often have poor performance status and multiple metastases, emphasizing the importance of pharmacist involvement for proper dosing, growth factor support, and comprehensive patient education about chemotherapy.
Watch
EP. 2: First-Line Focus: Molecular Testing and Guideline-Directed Therapy in EGFR-Positive NSCLC
April 18th 2025A panelist discusses how waiting for molecular testing results before initiating treatment for non–small cell lung cancer (NSCLC) is crucial because patients with EGFR mutations can avoid chemotherapy and immunotherapy in favor of targeted oral agents like osimertinib, which offer survival benefits with minimal toxicity compared to traditional treatments, while premature immunotherapy could cause severe immune-related adverse events that might preclude later use of more appropriate targeted therapies.
Watch
